News
AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...
A new microfluidic device promises to revolutionize kidney disease screening by enabling rapid, accurate, and low-cost ...
Zacks Investment Research on MSN14h
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder CancerAstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback